News | 10 May 2024
Medico Remedies posts Q4 FY24 PAT at Rs. 3.09 Cr
The company has posted net profit of Rs.8.29 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.8.29 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.615.82 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.118.82 crores for the Financial Year ended March 31, 2024
the campaign emphasizes the brand's reliability and effectiveness in providing timely relief
Ashland's nutraceuticals business supplies a broad portfolio of active ingredients and formulation aids to nutritional product companies
The company has posted net profit of Rs.171.42 crores for the Financial Year ended March 31, 2024
Wacker Biotech US, a wholly owned subsidiary of Wacker Chemie AG, specializes in the microbial production of pDNA
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Aptar Closures’ E-Disc Top securely protects against in-transit leakage while eliminating the need for liners and extra shipping preparation fees
The company has posted net loss of Rs. 105.07 crores for the Financial Year ended March 31, 2024
The project funding will be done through a mix of internal accruals and debts.
The brand has also unveiled a new TVC campaign in Telangana and Andhra Pradesh to drive brand awareness
The company has posted net profit of Rs.30.35 crores for the Financial Year ended March 31, 2024
The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024
The company has reported total income of Rs. 2,943.49 crores during the period ended March 31, 2024
The company has reported total income of Rs. 1,089.58 crores during the period ended March 31, 2024
The JV successfully leveraged the strengths of both companies to better serve the fast-growing Indian market
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Subscribe To Our Newsletter & Stay Updated
